The investigators reported that treatment with darolutamide reduced the risk of radiological progression or death by 49% in ...

Video content above is prompted by the following: Aqua Ablation Therapy Benefits Efficacy: Aqua ablation demonstrates noninferior, equal, or superior results compared with TURP (gold standard).

"The decision for which laser to use in your institution should be left up to the urologist and the hospital system," says Margaret A. Knoedler, MD. Data presented at the 2025 American Urological ...

Joseph Jacob, MD, outlines key findings on TAR-200 monotherapy from cohort 2 of the SunRISe-1 study. “If you look at the data, it's phenomenal data. It's the highest [complete response] CR rate ...

Welcome back to Pearls & Perspectives, with Amy Pearlman, MD! In this episode of Pearls and Perspectives, host Amy Pearlman, MD sits down with Andrew Y. Sun, MD, during the American Urological ...

Joseph Jacob, MD, outlines key findings on TAR-200 monotherapy from cohort 2 of the SunRISe-1 study. “If you look at the data, it's phenomenal data. It's the highest [complete response] CR rate ...

UGN-102 demonstrated a median duration of response of 24.2 months in low-grade, intermediate-risk NMIBC patients. The phase 2b study showed 65% complete response at 3 months, with 61% remaining ...

UGN-102 showed an 80.6% 18-month duration of response in low-grade intermediate-risk NMIBC patients achieving complete response at 3 months. The phase 3 ENVISION trial reported a 79.6% complete ...

Cretostimogene grenadenorepvec achieved a 75.5% complete response rate in high-risk, BCG-unresponsive NMIBC patients, with 97% remaining progression-free. The phase 3 BOND-003 trial demonstrated ...

In an interview with Urology Times®, John L. Gore, MD, MS, FACS, shares the background and key findings from the study, “Radical Cystectomy Versus Bladder-Sparing Therapy For Recurrent High-Grade ...

Higher levels of drinking water contaminants are associated with increased kidney stone burden and recurrence, independent of socioeconomic factors. The study analyzed over 1100 California residents, ...

A panelist discusses how clinicians should weigh the decision between enzalutamide and darolutamide for patients with metastatic hormone-sensitive prostate cancer (mHSPC) by considering each drug’s ...